Pharmaceutical companies are actively seeking acquisitions to bolster their pipelines and replace revenue from blockbuster drugs nearing patent expiration. However, industry leaders emphasize the importance of strategic patience, warning that rushing into deals out of desperation can lead to financially damaging outcomes.
The pressure to acquire new therapies is intense, as major pharmaceutical firms face the eventual decline in sales for their most profitable medications. This constant need for innovation drives merger and acquisition (M&A) activity, but the approach to these deals is evolving.
Executives highlight that companies performing well and not in immediate distress are better positioned to secure favorable terms and identify targets that genuinely align with their long-term strategic goals. The lesson learned from previous M&A cycles is that "shopping hungry"—making acquisitions under duress—often results in overpaying and integrating assets that do not deliver the expected value. This suggests a shift towards more deliberate and less opportunistic deal-making in the sector.